Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but missed on top-line and operating metrics due to pre-revenue status and one-time events. Net income (GAAP) of $123.2M ($1.08 EPS) significantly exceeded the $58.9M ($0.45 EPS) consensus, driven by a $178.2M gain from the sale of a Priority Review Voucher (PRV). However, zero product revenue was reported against a $16.5M expectation, as the recently approved KRESLADI™ has not yet reached commercial sales. Operating efficiency improved YoY following a 2025 restructuring, with R&D and G&A expenses down significantly.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Rocket Pharma(RCKT) the EBIT is -46.92 M (+30.67%), Beat estimate;the EPS is 1.08 (+274.2%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.02B--
----
EBITExceed expectations
-0.05B30.67%
-0.05B28.65%
+0.00B2.02%
EPSExceed expectations
1.08274.19%
0.3694159.59%
+0.7106114.60%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf